GlassScriptPhysician profile
Jorida Lulaj
NPI 1679973911
$2,098.00
in general payments reported to CMS, 2019-2025
29 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $402 · 2022: $833 · 2023: $151 · 2024: $450 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808 · Education: $55.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $807.67 |
| Education | $55.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $288.73 | 2021-2024 | Airsupra, Breztri, Fasenra |
| Electromed, INC. | $256.07 | 2024-2025 | Smartvest |
| Pulmonx Corporation | $176.21 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Regeneron Healthcare Solutions, INC. | $175.75 | 2022-2025 | Dupixent |
| United Therapeutics Corporation | $139.91 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.65 | 2022-2023 | Glassia |
| Baxter Healthcare | $119.14 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.53 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $80.27 | 2022-2023 | Opsumit, Uptravi |
| Insmed, INC. | $59.27 | 2021-2022 | |
| Mylan Specialty L.P. | $55.70 | 2022-2023 | Yupelri |
| Covis Pharma Gmbh | $51.74 | 2021 | |
| Glaxosmithkline, LLC. | $50.83 | 2021 | |
| Genzyme Corporation | $43.64 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $39.21 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $37.05 | 2021 | |
| Merck Sharp & Dohme LLC | $33.39 | 2022-2023 | Zerbaxa, Recarbrio |
| Advanced Respiratory, INC | $29.65 | 2021 | |
| Mallinckrodt Hospital Products INC. | $29.36 | 2022 | |
| Abbvie INC. | $28.49 | 2022 | |
| Gilead Sciences, INC. | $23.99 | 2021-2023 | Veklury |
| Inspire Medical Systems, INC. | $23.78 | 2025 | Inspire |
| Grifols USA, LLC | $23.29 | 2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $21.18 | 2021 | |
| Mayne Pharma Commercial LLC | $17.52 | 2021 | |
| Amgen INC. | $17.36 | 2022 | |
| Phadia US INC. | $14.15 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.85 | 2023 | Quviviq |
| Inogen, INC. | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorida Lulaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.